CARSGEN-B (02171): Abstracts for CT1190B and CT071 Published at the 2026 ASH Annual Meeting

CARSGEN-B (02171) announced that the abstracts for the research results of CT1190B (a universal CAR-T candidate targeting CD19/CD20) in the treatment of relapsed/refractory large B-cell lymphoma, and CT071 (an autologous CAR-T candidate targeting GPRC5D) in the treatment of relapsed/refractory multiple myeloma (R/R MM) and high-risk newly diagnosed multiple myeloma (HR-NDMM), have been published at the 68th American Society of Hematology (ASH) Annual Meeting. The research data for both candidate products will be presented in poster form at the ASH Annual Meeting. Updated data from the study of CT0596 (a universal CAR-T candidate targeting BCMA) in the treatment of R/R MM and primary plasma cell leukemia will be published in a separate company announcement in December 2026.